JP2012001565A5 - - Google Patents

Download PDF

Info

Publication number
JP2012001565A5
JP2012001565A5 JP2011219630A JP2011219630A JP2012001565A5 JP 2012001565 A5 JP2012001565 A5 JP 2012001565A5 JP 2011219630 A JP2011219630 A JP 2011219630A JP 2011219630 A JP2011219630 A JP 2011219630A JP 2012001565 A5 JP2012001565 A5 JP 2012001565A5
Authority
JP
Japan
Prior art keywords
patient
immunogenic composition
influenza virus
langerhans cells
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011219630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012001565A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012001565A publication Critical patent/JP2012001565A/ja
Publication of JP2012001565A5 publication Critical patent/JP2012001565A5/ja
Pending legal-status Critical Current

Links

JP2011219630A 2004-11-03 2011-10-03 インフルエンザワクチン接種 Pending JP2012001565A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62497304P 2004-11-03 2004-11-03
US60/624,973 2004-11-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007540074A Division JP2008519042A (ja) 2004-11-03 2005-11-03 インフルエンザワクチン接種

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014081555A Division JP2014132035A (ja) 2004-11-03 2014-04-11 インフルエンザワクチン接種

Publications (2)

Publication Number Publication Date
JP2012001565A JP2012001565A (ja) 2012-01-05
JP2012001565A5 true JP2012001565A5 (https=) 2013-04-11

Family

ID=36578359

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007540074A Pending JP2008519042A (ja) 2004-11-03 2005-11-03 インフルエンザワクチン接種
JP2011219630A Pending JP2012001565A (ja) 2004-11-03 2011-10-03 インフルエンザワクチン接種
JP2014081555A Pending JP2014132035A (ja) 2004-11-03 2014-04-11 インフルエンザワクチン接種

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007540074A Pending JP2008519042A (ja) 2004-11-03 2005-11-03 インフルエンザワクチン接種

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014081555A Pending JP2014132035A (ja) 2004-11-03 2014-04-11 インフルエンザワクチン接種

Country Status (9)

Country Link
US (2) US20090004222A1 (https=)
EP (2) EP2923711A1 (https=)
JP (3) JP2008519042A (https=)
CN (1) CN101076355A (https=)
AU (1) AU2005314563B2 (https=)
CA (1) CA2586690A1 (https=)
ES (1) ES2542020T3 (https=)
HK (1) HK1214534A1 (https=)
WO (1) WO2006062637A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2471552B1 (en) 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
RU2523587C2 (ru) * 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
CN102112151A (zh) * 2008-07-30 2011-06-29 久光制药株式会社 微针装置及由微针装置使日本脑炎病毒抗原的功效升高的方法
EP4241785B1 (en) * 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
BR112015018014A2 (pt) * 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CA3088485A1 (en) * 2018-01-18 2019-07-25 Etherna Immunotherapies Nv Lipid nanoparticles
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
JP2023523952A (ja) 2020-04-28 2023-06-08 ティコナ・エルエルシー マイクロニードルアセンブリ

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1122527A (en) 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
NZ240369A (en) 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
CA2156525A1 (en) 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9500788D0 (en) 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
ATE213646T1 (de) 1995-10-20 2002-03-15 Yissum Res Dev Co Grippe-impfstoff
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
CA2438960A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
EP2281573A3 (en) * 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
US20020193729A1 (en) * 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
KR20060135931A (ko) * 2004-04-01 2006-12-29 알자 코포레이션 인플루엔자 백신의 경피전달 장치 및 방법
EP2674486A1 (en) * 2007-06-18 2013-12-18 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide

Similar Documents

Publication Publication Date Title
JP2012001565A5 (https=)
JP2009173664A5 (https=)
AR083361A1 (es) Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
JP2013542247A5 (https=)
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
TW200722101A (en) Novel composition
JP2013505205A5 (https=)
NZ585674A (en) Vaccination with multiple clades of h5 influenza a virus
CR10559A (es) Vacuna de influenza
HRP20141258T1 (hr) 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat
WO2013098655A9 (en) Vaccines directed against human enteroviruses
JP2013536240A5 (https=)
JP2009539965A5 (https=)
NZ597000A (en) Compositions and methods for administration of vaccines against dengue virus
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2015520196A5 (https=)
MX2011008923A (es) Composicion inmunogena.
WO2012122725A1 (zh) 疫苗注射剂及其制备方法和用途
HRP20141063T1 (hr) Cjepivo protiv hpv
JP2015531389A5 (https=)
JP2014515035A5 (https=)
JP2016531895A5 (https=)
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
JP2016521754A5 (https=)
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers